How you and I created itThe EconomistOr, to put it more generally, media organs like this one. Things are tough for the media in … When I write something about a relatively non-divisive, curious issue like Indian voting rights, I may get a few dozen …
New Method May Improve Face Transplant Matches – Philly.com
|
New Method May Improve Face Transplant Matches
Philly.com “We found that if certain facial measurements were off by as little as 1 millimeter between donor and recipient, they were not the best match for transplant surgery.” Pomahac and colleagues conducted 61 virtual face transplantations representing donors … |
Pre-Open Stock Movers 10/10: (ACUR) (CHTP) (NFLX) Higher; (CTXS) (RT … – StreetInsider.com (subscription)
StreetInsider.com (subscription)Pre-Open Stock Movers 10/10: (ACUR) (CHTP) (NFLX) Higher; (CTXS) (RT …StreetInsider.com (subscription)This DMC recommendation is based on a predefined interim analysis showing highly statistically significant efficacy …
'Every heart in India is crying today': India mourns the retirement of Sachin … – The Independent
The Independent |
‘Every heart in India is crying today’: India mourns the retirement of Sachin …
The Independent “Every heart in India is crying today. Cricket is over.” On social media, cricket fan and government minister Shashi Tharoor declared that Tendulkar had been the “greatest Indian to wield a bat”. “He has given us all so much,” he added of the man with … Sachin Tendulkar to retire after 200th test, says ‘heart feels it’s time.’NDTV Sachin Tendulkar to retire after 200th, says heart feels it’s time!Indian Express Tendulkar to quit after 200th testReuters India Cricket Country –The Guardian all 353 news articles » |
Cardiac Biomarker ST2 Helps Assess Heart Failure Risk And Identify Heart … – EON: Enhanced Online News (press release)
|
Cardiac Biomarker ST2 Helps Assess Heart Failure Risk And Identify Heart …
EON: Enhanced Online News (press release) SAN DIEGO–(BUSINESS WIRE)–Critical Diagnostics announced today that results of the HF-ACTION study just published in the American Heart Association’s Circulation: Heart Failure demonstrate that levels of the biomarker ST2 are predictive of long-term … |
Indore: Quack's injection turns a girl into psychotic – Daily News & Analysis
Daily News & Analysis |
Indore: Quack’s injection turns a girl into psychotic
Daily News & Analysis … injectible, due to which she is into extrapyramidal symptom (EPS), which is a side affect of anti-psychotic medication.” The girl also developed typhoid, liver malfunction and high levels of blood ammonia during the treatment, the doctors at MY … |
Cardiac Biomarker ST2 Helps Assess Heart Failure Risk And Identify Heart … – 4-traders (press release)
|
Cardiac Biomarker ST2 Helps Assess Heart Failure Risk And Identify Heart …
4-traders (press release) Critical Diagnostics announced today that results of the HF-ACTION study just published in the American Heart Association’s Circulation: Heart Failure demonstrate that levels of the biomarker ST2 are predictive of long-term outcomes for people … |
Rituximab Biosimilar Market Opportunity Analyzed in New Research Report at … – PR Web (press release)
|
Rituximab Biosimilar Market Opportunity Analyzed in New Research Report at …
PR Web (press release) In this report “Therapy Class Overview: Rituximab biosimilar – http://www.reportsnreports.com/reports/269204-therapy-class-overview-rituximab-biosimilar.html ”, we have analyzed the market opportunity of rituximab biosimilar. What one would get if buy … |
Gilead halts leukaemia study on positive results – PMLiVE
|
Gilead halts leukaemia study on positive results
PMLiVE The trial – known as Study 116 – is comparing idelalisib plus Roche/Biogen Idec’s Rituxan (rituximab) to rituximab alone in patients unsuitable for treatment with conventional chemotherapy. At an interim analysis, the combination was found to have a … Gilead Stops Cancer Drug Trial Early On Positive ResultsNASDAQ UPDATE: Gilead to Stop Phase 3 Study 116 of Idelalisib in Chronic Lymphocytic …Benzinga Gilead stops leukaemia drug trial earlyPharmaTimes MarketWatch all 21 news articles » |
Alethia Biotherapeutics obtains US patent for use of anti-Siglec-15 antibodies – Pharmaceutical Business Review
|
Alethia Biotherapeutics obtains US patent for use of anti-Siglec-15 antibodies
Pharmaceutical Business Review The patent entitled ‘Polynucleotides and Polypeptide Sequences involved in the Process of Bone Remodeling’, provides broad protection for antibodies that target Siglec-15 and also having osteoclast differentiation or bone resorption inhibitory activity. |